| DOI | Trouver le DOI : https://doi.org/10.1007/s00044-011-9759-1 |
|---|
| Auteur | Rechercher : Bartusik, Dorota1; Rechercher : Tomanek, Boguslaw1 |
|---|
| Affiliation | - Conseil national de recherches du Canada. Institut du biodiagnostic du CNRC
|
|---|
| Format | Texte, Article |
|---|
| Sujet | magnetic resonance imaging; breast cancer cells; drug efficacy |
|---|
| Résumé | This study is aimed on Magnetic resonance imaging (MRI) modalities for monitoring Herceptin (trastuzumab) efficacy in breast cancer cells ex vivo. The efficacy profile of trastuzumab (0.010 μg/ml) was examined using T2 relaxivity measurements prior to and after 24, 48, and 72 h treatment. The untreated MCF-7 cells were considered as a control. MRI results show early tumor response to treatment while comparing pre- and post-treatment T2. The changes of T2 MRI correspond to tumor growth inhibition. The study shows that MRI can be used for the non-invasive monitoring of cancer cells’ death caused by immuno-targeting in preclinical testing of efficacy and treatment regimens. |
|---|
| Date de publication | 2011-08-02 |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Identificateur | 9759 |
|---|
| Numéro NPARC | 21268252 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | d7d49b8e-ab2a-4267-846a-c6753bd9dda6 |
|---|
| Enregistrement créé | 2013-06-10 |
|---|
| Enregistrement modifié | 2020-04-21 |
|---|
